Health Technology Santen Pharmaceutical Co., Ltd. Business Summary
Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.
Financial Highlights
Mar 2021
JPY USD Revenue 249,605M 2,353.48M Gross Profit 141,464M 1,333.84M Operating income 38,651M 364.43M Income before tax 12,776M 120.46M Net income 6,826M 64.36M EBITDA 55,843M 526.53M Diluted EPS 17.05 0.16 Dividends Per Share 28 0.26 Total Assets 402,353M 3,641.20M Total liabilities 95,305M 862.48M Total equity 307,585M 2,783.57M Operating cash flow 38,808M 365.91M Currency in JPY Currency in USD
Historical Data Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
199,096M
224,942M
234,026M
241,555M
249,605M
Gross Profit
115,763M
129,618M
134,165M
134,703M
141,464M
Operating income
33,301M
38,637M
41,242M
40,125M
38,651M
Income before tax
30,055M
39,261M
43,117M
32,091M
12,776M
Net income
21,717M
35,247M
31,953M
23,616M
6,826M
EBITDA
43,183M
49,533M
52,211M
56,698M
55,843M
Diluted EPS
52.76
86.42
78.43
59.00
17.05
Dividends Per Share
26
26
26
27
28
Total Assets
358,906M
388,463M
391,186M
408,768M
402,353M
Total liabilities
102,977M
100,904M
98,614M
106,208M
95,305M
Total equity
255,110M
285,823M
290,900M
302,865M
307,585M
Operating cash flow
10,843M
42,843M
32,894M
39,947M
38,808M
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
1,838.58M
2,029.56M
2,110.34M
2,221.69M
2,353.48M
Gross Profit
1,069.03M
1,169.49M
1,209.84M
1,238.92M
1,333.84M
Operating income
307.52M
348.60M
371.90M
369.04M
364.43M
Income before tax
277.54M
354.23M
388.81M
295.15M
120.46M
Net income
200.54M
318.02M
288.13M
217.20M
64.36M
EBITDA
398.78M
446.91M
470.81M
521.47M
526.53M
Diluted EPS
0.48
0.77
0.70
0.54
0.16
Dividends Per Share
0.24
0.23
0.23
0.24
0.26
Total Assets
3,220.90M
3,652.68M
3,534.22M
3,786.46M
3,641.20M
Total liabilities
924.14M
948.79M
890.94M
983.81M
862.48M
Total equity
2,289.41M
2,687.56M
2,628.17M
2,805.47M
2,783.57M
Operating cash flow
100.13M
386.55M
296.62M
367.41M
365.91M
Valuation Measures
Mar 2021
PER 89.12 ROA 1.68% ROE 2.23% Operating margin 15.48% Profit margin 2.73%
Key executives
President, CEO & Representative Director:
Shigeo Taniuchi
CFO, General Manager-Finance & Administration:
Kazuo Koshiji
Chief Information Officer, GM-Digital & IT:
Minori Hara
Chief Compliance Officer & Executive Officer:
Mika Masunari
Executive Officer:
Kenji Morishima Shareholders
MFS International (UK) Ltd. (4.8%)
Massachusetts Financial Services Co. (4.3%)
Mitsubishi UFJ Financial Group, Inc. (3.4%)
Nomura Asset Management Co., Ltd. (2.9%)
Nippon Life Insurance Co. (2.6%)
The Vanguard Group, Inc. (2.2%)
Ono Pharmaceutical Co., Ltd. (2.1%)
Eisai Pension Fund (1.7%)
BlackRock Fund Advisors (1.6%)
Black Creek Investment Management, Inc. (1.6%)
Contact Details Website: http://www.santen.co.jp Address:
Grand Front Osaka Tower A, 25/F,
4-20 Ofuka-cho,
Osaka,
530-8552,
Japan
Phone:
+81.6.7664.8621
Related Companies
Santen Pharmaceutical (Hong Kong) Ltd.
Phacor, Inc.
Santen Canada, Inc.
Santen Pharmaceutical Restricted Stock Compensation Plan
Santen Philippines, Inc.
Santen Pharma Malaysia Sdn. Bhd.
Santen (Thailand) Co., Ltd
Santen SA
Santen Eye Care Co., Ltd.
Santen Business Services Co., Ltd.
Claire Co., Ltd.
Santen Italy Srl
Santen Pharmaceutical Spain SL
SantenPharma AB
Santen India Pvt Ltd.
Santen Pharmaceutical Korea Co., Ltd.
Santen Pharmaceutical Asia Pte Ltd.
Santen Pharmaceutical Sales & Marketing (Suzhou) Co., Ltd.
Taiwan Santen Pharmaceutical Co., Ltd.
Santen SAS
Santen Pharmaceutical Trust
Santen Pharmaceutical (China) Co., Ltd.
Santen Holdings U.S., Inc.
Santen Pharmaceutical Pension Fund
Santen GmbH
Santen Oy
Santen Holdings EU BV
InnFocus, Inc.
Santen, Inc.
Star Ab Oy
Competitors
Zhaoke Ophthalmology Ltd.
Nicox SA
EyePoint Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc.
G-treeBNT Co., Ltd.
CHO Pharma, Inc.
Satellos Bioscience Inc
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 17 Sep, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
